What question did this study set out to answer?

This research aims to develop CAR T cell therapy targeting mesothelin for treating cholangiocarcinoma.

January 18, 2026Hepatology CommunicationsOpen Access

Preclinical development of mesothelin-targeting CAR T cells for the treatment of cholangiocarcinoma

View Full Paper

Ask AI

Bookmark

This research aims to develop CAR T cell therapy targeting mesothelin for treating cholangiocarcinoma.
Assessed mesothelin expression in cholangiocarcinoma tissue samples from Thai patients.
Generated CAR T cells using various single-chain variable fragment constructs targeting mesothelin.
Evaluated cytotoxicity of CAR T cells in preclinical mouse models of cholangiocarcinoma.
Mesothelin was strongly expressed in 79% of cholangiocarcinoma specimens.
hYP218-based CAR T cells eradicated tumors in all three mouse models.
hYP218 CAR T cells demonstrated strong persistence with low PD-1 expression.

No takes yet. Share an insight, caveat, or question.

Preclinical development of CAR T cells targeting mesothelin shows promise against cholangiocarcinoma, suggesting a novel therapeutic approach.

Duangdara et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Preclinical development of CAR T cells targeting mesothelin shows promise against cholangiocarcinoma, suggesting a novel therapeutic approach.